PureTech Health

PRTC · Main Market · Health Care · mcap £262m · 111.0p

PureTech founds and part-owns biotech companies, developing some programmes itself before spinning them into separate 'Founded Entities' funded by outside investors. It earns returns through equity stakes, milestones and royalties.

Briarwood Chase Management LLC 8 May – 7 Oct · 2 notices

below 3% → 10.1%

share price at the notices 110.2–127.2p · now 111.0p 8 May 2026 7 Oct 2026

Tang Capital Management, LLC 19 Sep – 25 Sep · 5 notices

below 3% → 7.1%

share price at the notices 114.4–139.0p · now 111.0p 19 Sep 2025 1 Oct 2025 24 Apr 2026 28 Aug 2026 25 Sep 2026

On September 19 19 Sep · 1 notice

6.3% → 6.4%

share price at the notices 120.2p · now 111.0p 19 Sep 2025

Citigroup Inc. 23 Sep – 18 Sep · 16 notices

5.6% → 5.9%

share price at the notices 119.0–138.8p · now 111.0p 23 Sep 2025 9 Oct 2025 14 Oct 2025 17 Oct 2025 7 Nov 2025 18 Nov 2025 16 Apr 2026 27 Apr 2026 7 May 2026 22 May 2026 27 May 2026 29 May 2026 4 Jun 2026 4 Sep 2026 18 Sep 2026

Citigroup Inc. reported that on September 2 4 Sep – 10 Oct · 2 notices

0.4% → 5.7%

share price at the notices 116.4–130.6p · now 111.0p 4 Sep 2025 10 Oct 2025

Baillie Gifford & Co 10 Dec · 1 notice

5.3% → 4.8%

share price at the notices 123.2p · now 111.0p 10 Dec 2025

Directors

other 6 Mar 2024

other 20 Jun 2024

other 27 Jun 2024

other 22 Aug 2024

other 31 Oct 2024

other 27 Feb 2025

other 4 Jul 2025

other 8 Jul 2025

purchase On September 24, 2025, PureTech Health plc announced that several of its directors purchased ordinary shares in the market between September 22-23, 2025. Robert Lyne, Interim Chief Executive Officer, purchased 81,051 sha 24 Sep 2025

award PureTech Health plc announced that a person discharging managerial responsibilities, Eric Elenko, received 112,509 ordinary shares on March 12, 2026, following the vesting of restricted share units granted on May 22, 202 13 Mar 2026

purchase PureTech Health plc announced that several Persons Discharging Managerial Responsibilities (PDMRs), including the Chief Executive Officer and Non-Executive Directors, purchased an aggregate of 147,849 ordinary shares on 9 Jul 2026

award PureTech Health plc announced that 33% of restricted share units granted on June 26, 2024, vested on June 26, 2026, and were issued to directors and PDMRs on July 14, 2026. The market price used for calculation was 119.2 17 Jul 2026

award PureTech Health plc announced that restricted share units granted to non-executive directors vested in full on June 9, 2026, with ordinary shares issued on July 29, 2026. A total of 469,720 ordinary shares were issued at 31 Jul 2026

award PureTech Health plc announced that 33% of restricted share units granted to directors and PDMRs on November 19, 2025, vested on August 1, 2026, and were issued on August 17, 2026. The market price used for calculation wa 18 Aug 2026

Company filings. Not investment advice.